Possible Cause for Bowel Cancer Therapy Resistance Identified
Complete the form below to unlock access to ALL audio articles.
Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, they also make it resistant to common forms of chemotherapy. This discovery was made by a research team led by Martin Luther University Halle-Wittenberg (MLU) in cooperation with Saarland University. For its new study, published in the scientific journal "Molecular Cancer", the team analysed more than 140 tissue samples from bowel cancer patients and found there was a link between the concentration of IGF2BP2 and the characteristics of the tumours. The findings could help to develop better diagnostic procedures and possibly new forms of therapy in the future.
According to the Robert Koch Institute, bowel cancer is one of the most common cancers in Germany. In 2019, 58,967 men and women were diagnosed with it. "If caught early, bowel cancer can be removed quite well by surgery and it is therefore often curable," says the leader of the study, Professor Sonja Kessler from the Institute of Pharmacy at MLU. Once the disease has progressed, surgery is often no longer an option. In some cases, tumours can develop resistance to common forms of chemotherapy, which means they no longer respond to treatment. "We still do not know how and why some tumours develop this resistance. Currently, there are no reliable tests that can predict this at an early stage," Kessler adds.
For the new study, the team led by the pharmacist from MLU examined more than 140 tissue samples from patients suffering from bowel cancer. The aim was to find distinctive traits in the samples which do not occur in healthy individuals and which could possibly explain the different tumour characteristics. The scientists found what they were looking for in the protein IGF2BP2. "It is actually a growth protein that is predominantly active during embryonic development.
According to Kessler, these findings are highly relevant for medicine and could be applied in two ways. "One could develop a biomarker, that means a test to determine the characteristics of the tumour at an early stage and to align treatment accordingly," says the pharmacist. Another application would be to develop active substances that specifically inhibit the activity of IGF2BP2 in tumours and thus might be able to reverse resistance to chemotherapy drugs. "Further research needs to be conducted to confirm whether this is indeed possible. We still don’t know enough about how IGF2BP2 precisely intervenes in the metabolism of cancer cells," Kessler concludes. Only after these questions have been answered, large-scale clinical trials could determine and verify the efficacy of potential active substances in humans.
Reference: Kendzia S, Franke S, Kröhler T, et al. A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer. Mol Cancer. 2023;22(1):89. doi: 10.1186/s12943-023-01787-x
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.